SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 27, Issue 2, 2009, Pages 314-315

How should we prescribe lapatinib to our patients: Once daily or twice daily, and at what dose?

(2) Ciccarese, Mariangela a Lorusso, Vito a

a VITO FAZZI HOSPITAL (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; LAPATINIB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; TAXOID;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; DRUG BIOAVAILABILITY; DRUG COST; FOOD; FOOD DRUG INTERACTION; HUMAN; LETTER; MAXIMUM TOLERATED DOSE; PRESCRIPTION; PRIORITY JOURNAL; SOLID TUMOR; BREAST TUMOR; DOSE RESPONSE; DRUG ADMINISTRATION; METABOLISM; NOTE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FILGRASTIM; HUMANS; QUINAZOLINES; TAXOIDS;

EID: 58249091534 PISSN: 0732183X EISSN: None Source Type: Journal
DOI: 10.1200/JCO.2008.20.0345 Document Type: Letter

Times cited : (5)

References (11)

1
- 46449113024
- Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
- Gomez HL, Doval DC, Chavez MA, et al: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999-3005, 2008
- (2008) J Clin Oncol , vol.26 , pp. 2999-3005
- Gomez, H.L.¹ Doval, D.C.² Chavez, M.A.³

2
- 34447498580
- Lapatinib
- Moy B, Kirkpatrick P, Kar S, et al: Lapatinib. Nat Rev Drug Discov 6:431-432, 2007
- (2007) Nat Rev Drug Discov , vol.6 , pp. 431-432
- Moy, B.¹ Kirkpatrick, P.² Kar, S.³

3
- 20844437246
- Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects
- Bence AK, Anderson EB, Halepota MA, et al: Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 23:39-49, 2005
- (2005) Invest New Drugs , vol.23 , pp. 39-49
- Bence, A.K.¹ Anderson, E.B.² Halepota, M.A.³

4
- 84871469345
- US Food and Drug Administration Center for Drug Evaluation and Research: Application 22-059. http://www.fda.gov/cder/foi/nda/2007/022059s000-ClinPharmR. pdf
- US Food and Drug Administration Center for Drug Evaluation and Research: Application 22-059. http://www.fda.gov/cder/foi/nda/2007/022059s000-ClinPharmR. pdf

5
- 34548167457
- A phase I, open-label, three-period, randomized crossover study to evaluate the effect of food on the pharmacokinetics of lapatinib in cancer patients
- suppl
- Reddy N, Cohen R, Whitehead B, et al: A phase I, open-label, three-period, randomized crossover study to evaluate the effect of food on the pharmacokinetics of lapatinib in cancer patients. Clin Pharmacol Ther 81:S16-S17, 2007 (suppl)
- (2007) Clin Pharmacol Ther , vol.81
- Reddy, N.¹ Cohen, R.² Whitehead, B.³

6
- 33845886440
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer
- Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
- (2006) N Engl J Med , vol.355 , pp. 2733-2743
- Geyer, C.E.¹ Forster, J.² Lindquist, D.³

7
- 34548178015
- The value meal: How to save $1,700 per month or more on lapatinib
- Ratain MJ, Cohen EE: The value meal: How to save $1,700 per month or more on lapatinib. J Clin Oncol 25:3397-3398, 2007
- (2007) J Clin Oncol , vol.25 , pp. 3397-3398
- Ratain, M.J.¹ Cohen, E.E.²

8
- 46449138403
- Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer
- LoRusso PM, Jones SF, Koch KM, et al: Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 26:3051-3056, 2008
- (2008) J Clin Oncol , vol.26 , pp. 3051-3056
- LoRusso, P.M.¹ Jones, S.F.² Koch, K.M.³

9
- 33845303711
- Pharmacodynamic studies in drug development
- Hidalgo M, Messersmith W: Pharmacodynamic studies in drug development. Am Soc Clin Oncol Ed Book 160-163, 2004
- (2004) Am Soc Clin Oncol Ed Book , vol.160-163
- Hidalgo, M.¹ Messersmith, W.²

10
- 33745612994
- Methodology of clinical trials with new molecular-targeted agents: Where do we stand?
- suppl 7
- Morabito A, Di Maio M, De Maio E, et al: Methodology of clinical trials with new molecular-targeted agents: Where do we stand? Ann Oncol 17:vii128-vii131, 2006 (suppl 7)
- (2006) Ann Oncol , vol.17
- Morabito, A.¹ Di Maio, M.² De Maio, E.³

11
- 23944476155
- Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
- Burris HA III, Hurwitz HI, Dees EC, et al: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305-5313, 2005
- (2005) J Clin Oncol , vol.23 , pp. 5305-5313
- Burris III, H.A.¹ Hurwitz, H.I.² Dees, E.C.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.